Novo just wouldn’t Qwint: FDA clears weekly insulin Awiqli
A regulatory plod that began in 2023 – and met with success in many other territories – at last crossed the U.S. FDA finish line when Novo Nordisk A/S secured approval of Awiqli (insulin icodec) injection 700 units/mL, the first and only once-weekly, long-acting basal insulin.
RO
randy osborne
via Bioworld
Updated 2h ago

Source Verification
Corroboration Score: 1This story was independently reported by 1 sources. Click any source to read the original article.
Comments
0 commentsBe respectful and constructive.
Loading comments...
Previous
After a decade as a Yale hospital janitor, she is now a doctor there
Next
Microsoft Issues Statement On Why 'This Is An Xbox' Campaign Has Been Retired
Related Articles
ScienceManhattan Beach Named Among Best Best Places To Live In California By Research Firm
Patch-12h ago-1 sources
ScienceX-ray laser experiment unlocks water's hidden critical state at -81°F - Interesting Engineering
Google News-12h ago-1 sources
RPCAU scientists produce state’s first Sahiwal calves using IVF technology
The Times Of India-12h ago-1 sources